Citius Oncology
CTOR
19 hedge funds and large institutions have $9.2M invested in Citius Oncology in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
36% more funds holding
Funds holding: 14 → 19 (+5)
4% more capital invested
Capital invested by funds: $8.83M → $9.2M (+$366K)
0.93% less ownership
Funds ownership: 16.14% → 15.21% (-0.93%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$237K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$72.2K |
| 3 |
VF
Virtu Financial
New York
|
+$17.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$385K |
| 2 |
BlackRock
New York
|
-$29.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$7.27K |
CTOR Hedge Fund Activity: Q2 2026 in Review
19 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q2 2026, worth a combined $9.2M — up 4.2% from $8.83M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CTOR positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, adding an estimated $237K. The largest seller was Armistice Capital, cutting an estimated $385K.
- 19 institutional investors held Citius Oncology (CTOR) as of Q2 2026, up from 14 in Q1 2026.
- Funds reported $9.2M of Citius Oncology stock for Q2 2026, up 4.2% quarter-over-quarter.
- 7 funds opened new Citius Oncology positions in Q2 2026 and 2 closed out, a net change of +5 holders.
- The largest Citius Oncology buyer in Q2 2026 was UBS Group, an estimated $237K added.
- The largest Citius Oncology seller in Q2 2026 was Armistice Capital, an estimated $385K sold.
Based on aggregated 13F filings for Q2 2026.